Nektar Therapeutics (NKTR) Earnings Call Transcript & Summary

February 28, 2022

NASDAQ US Health Care Pharmaceuticals earnings 59 min

Earnings Call Speaker Segments

Jennifer Ruddock

executive
#1

Crystal, thanks, and good afternoon to all of you. We appreciate your joining us today. Participating on this call are our President and CEO, Howard Robin; our COO and CFO, Gil Labrucherie; Dr. Jonathan Zalevsky, who serves as our Chief of Research and Development; and our Chief Medical Officer, Dr. Dimitry Nuyten. During this call, we anticipate delivering forward-looking statements about our business, covering clinical trial enrollment and clinical trial results, the timing of and plans for upcoming clinical trials, the timing of and plans for upcoming presentations of clinical data, the therapeutic potential of our drug candidates, outcomes of and plans for health regulatory actions and decisions, financial guidance, and certain other statements concerning the future of our business. Since such forward-looking statements pertain to the future, they carry inherent uncertainties and risks that are hard to predict, and many of them lie beyond our control. Our actual results could differ materially from what these statements indicate. Significant risks and uncertainties appear in the Form 10-Q we filed on November 5, 2021, which you can find at sec.gov. We assume no obligation to update any of these forward-looking statements, whether because of new information, future developments, or otherwise. A webcast of this call will be accessible on the Investor Relations page of Nektar's website at nektar.com. Before I hand things over to Howard, I want to remind everyone that because we are calling in from different locations, I will moderate the Q&A session for our team so that we can steer clear of technical issues during the session. We appreciate your patience during this time. Having said that, I would like to hand the call over to our President and CEO, Howard Robin. Howard?

Howard Robin

executive
#2

Thanks, Jennifer. I want to thank each of you for joining us today. In many areas of our operations, 2021 was a standout year—both for the strides we took and for the way we delivered, and we continue to reinforce Nektar's position at the forefront of developing cytokine therapeutics for oncology and autoimmune conditions. We're excited about three late-stage registrational trial results expected in the first six months of this year from the BEMPEG program. If those trials prove successful, they'll position us for regulatory clearances and global commercialization in several major first-line cancer indications, such as melanoma, renal cell carcinoma, and bladder cancer. We're preparing the company for potential regulatory submissions and for launching BEMPEG commercially. Also, because we have breakthrough status for first-line melanoma, our expectation is that favorable Phase III results would allow us to accelerate the U.S. submission process for BEMPEG in that indication. So it's possible that BEMPEG could start reaching cancer patients in the later months of this year or at the start of 2023. Beyond the three trials that will report during the first half of this year, we have multiple additional registrational trials already running — one combining it with nivolumab for melanoma in the adjuvant setting and bladder cancer in the periadjuvant setting, and another pairing it with pembrolizumab for first-line head and neck cancer. So we designed our BEMPEG registrational effort, which spans the globe, to zero in on the cancer categories that matter most — the ones where we think pairing BEMPEG with a checkpoint inhibitor could deliver real clinical value to a sizable patient population. In those indications alone, checkpoint inhibitor revenue today is above $6 billion. Our aim is to make BEMPEG the first IL-2 therapy of its kind, and our development plan is built around getting it into frontline use for as many patients as possible. When you look at the IL-2 therapies currently being developed, BEMPEG stands apart as the sole candidate that packs 3 distinct advantages into one therapy. To start, BEMPEG was built so that signaling favors the beta-gamma arm of the IL-2 pathway, though it still binds briefly to the alpha receptor, something required for priming T cells within the lymph nodes. Next, by using full amp IL-2, we avoided the kinds of therapeutic difficulties that can arise with mutant structures. Finally, the prodrug approach behind BEMPEG allows continuous pathway signaling and lowers the toxicities associated with high-dose IL-2, all while providing an antibody-like dosing schedule that is simple to pair with a ready checkpoint inhibitor. Within the registrational trial we are running as our first-line study, these characteristics give us meaningful edges over rivals, and they render the developmental route in these cancers extremely challenging for any competing IL-2 effort still confined to far earlier phases of study. Because we hold the leading position in creating cytokine-based medicines, our subsequent candidate, NKTR-255, targets the IL-15 biological route, enabling us to activate the body's defenses via expansion of natural killer cells — something we see as carrying wide-ranging treatment promise across both solid and liquid tumor types. JZ will walk everyone through how that candidate is advancing afterward on this call. On the autoimmune front, our NKTR-358 effort — a collaboration with Eli Lilly — is also advancing at a strong clip. Lupus, ulcerative colitis and atopic dermatitis are the major indications we're targeting for NKTR-358, and existing products approved in those categories generate somewhere between $12 billion and $15 billion in sales. That makes this a very valuable program for Nektar; the Lilly agreement gives us substantial double-digit royalties ranging from the mid-teens up to the low 20s, and on top of that we have a co-promotion option. When you look at how NKTR-358 works across the board and the potential it holds for many autoimmune and inflammatory conditions, we can't help but feel real enthusiasm about the size of the opportunity in front of us. The design of NKTR-358 is that of a biologic monotherapy, delivered subcutaneously, targeting a variety of autoimmune conditions. Our partner Eli Lilly presented the initial proof-of-concept results for NKTR-358 in atopic dermatitis at their Annual Investor Meeting in December, and we were glad to see it. Lilly and Nektar both recognize the strong promise these findings demonstrate for this potential resolution therapeutic. Lilly has announced three Phase II trials for the NKTR-358 development program, covering lupus, ulcerative colitis, and atopic dermatitis, and a fourth Phase II study is also in the works. When it comes to harnessing the novelty regulatory cell biology, NKTR-358 is clearly ahead—both in the breadth of our efforts and how far along we are. Also, JZ will take a few minutes later on this call to walk through the enormous strides we made with NKTR-358 during 2021. Since many of you are focused on this, I'll now turn to BEMPEG, which is in development alongside the checkpoint inhibitors nivolumab and pembrolizumab. To build on what I said before, three trials should produce top-line results during the opening six months of this year. The Phase III melanoma readout comes first, then renal cell carcinoma, and bladder cancer after that. Should those trials succeed, they would pave the way for a sequence of regulatory registrational submissions covering BEMPEG plus nivo, and afterward commercial rollouts of the doublet regimen could start as soon as late 2022 or early 2023. Responsibility for every distribution, pricing and market access effort related to BEMPEG sits with Nektar. Promotional work will be divided between Nektar and BMS; as we move forward toward regulatory filings and launch, we're eager to collaborate closely with BMS. Just to note, Nektar records the full top-line for BEMPEG and keeps 65% of the profit. Our estimate is that patent exclusivity covering the BEMPEG plus anti-PD-1 antibody combo runs through at least February 2035. During January's JPMorgan conference, I mentioned that BMS and Nektar told investors Phase III melanoma data would arrive before April ends, and we anticipate results soon after from the two trials Nektar is conducting in renal cell carcinoma and bladder cancer. When it comes to the timing of these top line data, BMS and Nektar aren't giving any further specifics, since with the majority of late-stage trials run through a partnership, the intention of our company is to make one joint announcement. Just to remind everyone, and like we said before, the first 2 co-primary end points, ORR and PFS, are what we anticipate reporting top line results for. Should the melanoma study produce positive PFS results, our plan is to file for regulatory approval in the U.S. and Europe at essentially the same time. Any potential approval and country launches in Europe would naturally come after a potential U.S. approval and launch, given that the European regulatory review and approval process usually takes longer; and again, a reminder that Nektar stands to receive up to $1.4 billion in total milestones tied to BEMPEG filings and first commercial sales after approvals, and Gil is going to give more detail on the timing and triggers for those milestones shortly, when he walks through our 2022 financial guidance. Like I mentioned before, JZ is going to walk through the NKTR-255 program afterward on today's call, though I'd like to highlight a handful of significant wins for that program during 2021. To begin with, we generated meaningful preliminary results when combining the drug with cetuximab in solid tumors, during the initial dose escalation stage of our Phase I trial for NKTR-255, and those findings led to an exciting new partnership for NKTR-255 involving Merck KGaA and Pfizer. Through that arrangement, avelumab will be given together with NKTR-255 as part of Merck's Phase II JAVELIN Bladder Medley umbrella study. This will be a sizable randomized Phase II head-to-head trial, with Merck serving as sponsor and operator while we provide NKTR-255. One arm will receive avelumab as the comparator, and the study population will be bladder cancer patients in the maintenance setting—an indication that only avelumab holds. Merck's backing means a great deal to us, and we're glad they see the same promise we do in NKTR-255 paired with avelumab, whose ADCC mechanism has been shown in preclinical work. Separately, at ASH we recently presented findings pointing to NKTR-255's ability to boost CAR-T activity: patients given NKTR-255 showed CAR-T cell counts several times higher than their starting levels, and that effect was still evident twelve months on from their CAR-T treatment. We've got some news we're thrilled to share today: the FDA has given us the green light on our IND for a trial that will look at NKTR-255 when used alongside CAR-T treatments — CD19 CAR-T in particular. The Fred Hutchison Cancer setting is where this will kick off, running as an investigator-sponsored study. On the operational side, our balance sheet is in remarkably good shape, and we finished the year holding about $800 million in cash. That money, combined with support from our strategic collaborations and as much as $1.4 billion we could receive through regulatory filings and first commercial sales milestones for BEMPEG, provides a solid financial base for carrying out our ambitious development plans. Having said that, I'll now turn things over to Dr. Dimitry Nuyten, to continue. Thank you. Dimitry?

Dimitry Nuyten

executive
#3

Thanks, Howard. Before I give you an update on the BEMPEG trials, I want to briefly revisit how it works and what our approach has been. When we began developing BEMPEG, the aim was to build a completely new molecule that would keep what's beneficial about IL-2 while solving the longstanding issues tied to high-dose IL-2. Using our technology platform, we managed to engineer a product candidate that we consider best-in-class. Let me walk through a few of the ways BEMPEG stands apart. First, we signal preferentially through the beta-gamma IL-2 receptors, which drives cytotoxic T-cell growth; we achieve this without over-activating cell populations, something that can cause the immune system to be down-regulated; and in contrast to mutated IL-2 forms that bind only the beta-gamma receptors, we keep some transient binding to the alpha receptor; because of that, we can improve T-cell priming within lymph nodes, which allows T cell proliferation and lets those T-cells infiltrate tumors once the new tumor antigen is presented. Second, rather than a mutated version, we relied on the full length IL-2 molecule with no amino acid substitutions. That way, we avoid any tachyphylaxis on the receptor, as well as the problems mutant versions can show over time in vivo, such as antidrug antibodies, which reduce efficacy as time goes on. Third, being a prodrug, BEMPEG sidesteps the cytokine storm risk that a non-product approach can carry. That's definitely something you want to steer clear of in a medicine with the potential to treat so many cancer patients. And last, we've gotten an antibody-like dosing schedule in an outpatient setting that combines easily with checkpoint inhibitors, rather than the intense and dense regimen for high-dose IL-2 that's typically administered in an intensive care unit. We are combining BEMPEG with checkpoint inhibitors, and this combination is really quite simple and elegant. It's known that targeting the PD-1 pathway may strengthen the immune response by reactivating cytotoxic T-cells that have been halted by the PD-L1 and PD-1 signaling access. We view this as taking the brakes off the immune system, an effective approach on its own; then, by preferentially targeting the IL-2 pathway to significantly raise the number of cytotoxic immune cells in the tumor microenvironment, we put our foot on the gas. In our earlier clinical studies, we've demonstrated 2 important things. First, that treatment with BEMPEG upregulates PD-1 on these new immune cells; and secondly, that this ultimately leads to upregulation of PD-L1 in the tumor microenvironment. Both are expected biological outcomes following BEMPEG treatment, and the end result is that the 2 together, BEMPEG plus nivolumab, could potentially drive deeper and more durable responses in patients. Let me now give a brief update of the timing for our registrational studies, which are tracking in line with our prior guidance. To start, regarding the 760-patient Phase III study in first-line metastatic melanoma that our partner BMS is running, both we and BMS are eagerly anticipating a near-term readout of top line data. Keep in mind this readout will cover top line results for the 2 co-primary end points. Later in the year, we intend to share the complete data set, and possibly subset analyses, at a medical meeting. We aren't giving specifics yet about which meeting that will be, but our aim is a major oncology conference. As a reminder, this Phase III trial is well-powered and well-designed, with 3 co-primary end points: overall response rate, progression-free survival and overall survival. As I mentioned, the initial analysis will cover the 2 co-primary end points of overall response rate and progression-free survival; for registrational purposes, meeting the progression-free survival end point alone is sufficient for us to file with the regulatory authorities. Quite a few of you have requested specifics about the statistical analysis plan for this study, and like most companies, we haven't disclosed full details on that ahead of full data publication. Previously, we offered the design of CheckMate 067 as a reference example. In our Phase II melanoma cohort, the median PFS we observed for our doublet was 30.9 months; we're aware that the I-O doublet treatments currently available for first-line melanoma patients in Phase III studies have shown a median PFS in the 10- to 11-month range, and nivolumab, the global standard of care comparator still commonly used in our Phase III study, has shown a median PFS between 4 to 6 months across different studies. As we head toward our top line results, we're highly enthusiastic, based on our previously reported Phase II results, that BEMPEG plus nivolumab might potentially produce results that position it well within the current treatment landscape; we see a unique opportunity for BEMPEG plus nivolumab doublets if we can emerge as a new standard of care in this setting. The next Nektar study now underway is a 620-patient Phase III trial in first-line renal cell carcinoma evaluating BEMPEG plus nivolumab against a TKI of physician choice, either sunitinib or cabozantinib; we anticipate possibly reaching our first interim analysis for the co-primary end point of overall survival at some point in the second quarter of 2022. At that point, we could also perform a final ORR analysis for the co-primary end point. Should we fail to pass the preset threshold for statistical significance at the first interim analysis, the Data Monitoring Committee will advise resizing events for the final overall survival analysis. BMS and Nektar are pursuing a comprehensive approach to developing BEMPEG plus nivolumab in this particular tumor type. On top of that, BMS is running a randomized Phase II trial with 250 patients in RCC, testing BEMPEG plus nivolumab alongside Exelixis cabozantinib, so that a comparison can be made against the nivolumab and cabozantinib doublet, clearing a path toward a TKI inclusive regimen in RCC using BEMPEG and nivolumab. During the prior year, BMS and Nektar broadened their RCC strategy by bringing in a new collaboration with Exelixis, which will run a trial assessing BEMPEG plus nivolumab together with their next generation TKI, called XL092. That trial will further encompass additional geo cancers, ureteral cancer among them. Turning to the Phase II trial in first-line cisplatin-ineligible urothelial carcinoma that Nektar is conducting, its design is meant to support a possible filing seeking accelerated approval. Enrolled in this trial are roughly 110 cisplatin-ineligible urothelial carcinoma patients whose baseline CPS score is 10 or lower, used as a measure of PD-L1 expression, and these patients represent the population facing the greatest unmet medical needs, since they cannot get the most effective chemotherapy regimen available for bladder cancer, and checkpoint inhibitors have demonstrated most of their benefit among patients whose tumors are PD-L1 high. Overall response along with duration of response, as determined through central radiology review, serve as the primary end point for this trial.

Dimitry Nuyten

executive
#4

To get a strong, mature data set, we intend to reach at least 18 months of follow-up while measuring how long responses last, and we anticipate the initial results from this trial to also arrive during the first half of 2022. As Howard mentioned before, the BEMPEG nivolumab program additionally includes 2 sizable Phase III trials, one for muscle invasive bladder cancer and another for adjuvant melanoma. Our collaborator, BMS, is conducting the Phase III periadjuvant muscle invasive bladder cancer study; it aims to enroll roughly 540 patients who cannot receive cisplatin and who will be given BEMPEG plus nivolumab or nivolumab by itself, initially in a neoadjuvant phase before radical cystectomy and afterward in the adjuvant phase for 12 months after surgery. The trial also features a third reference arm in which patients undergo cystectomy only, with no additional neoadjuvant or adjuvant therapy; we anticipate the initial data readout during 2024 or 2025. This trial is likewise intended to act as a confirmatory study supporting our planned possible accelerated approval in metastatic cis-ineligible urothelial carcinoma. Nektar is conducting the Phase III adjuvant melanoma trial; it is enrolling about 950 patients in total for a 12-month postsurgery treatment period, with recurrence-free survival by blinded independent central review as the end point. Enrollment here has surpassed our timeline projections, and we now expect to finish enrolling the 950-patient study around the middle of the year. The adjuvant trial is meant to expand on the recent approval of nivolumab in this setting and widen the role for BEMPEG in the adjuvant setting. Initial data from the trial are projected to become available in 2024. For our combination trials with pembrolizumab, we are enrolling patients in our Phase II/III study of more than 500 patients, intended to support registration in first-line head and neck cancer; we have partnerships established with both Merck and SFJ Pharmaceuticals for the trial, and we are highly enthusiastic about this chance to serve a large patient population in the frontline setting; it incorporates an interim analysis of overall response rate once 200 patients have been enrolled. And if overall response rate clears a prespecified fertility boundary, the trial will proceed and the remaining 300 patients will be enrolled into the Phase III portion of the study. Given the favorable competitive landscape, we view this as a unique opportunity for us to establish BEMPEG as the first IL-2 mechanism for treating head and neck cancer. And finally, we are continuing to move our PROPEL study forward with the addition of chemotherapy to the BEMPEG plus pembrolizumab treatment regimen in both squamous and non-squamous non-small cell lung cancer patients whose PD-L1 expression levels are under 50%. Pairing it with chemotherapy lets us think about a wide registrational approach for BEMPEG in non-small cell lung cancer among those patient groups whose tumors show negative to low and medium PD-L1 expression, and who right now face the greatest unmet need for improved therapeutic choices. We're eager to share upcoming updates on how our work with BEMPEG moves forward. Now I'll hand the call over to JZ.

Jonathan Zalevsky

executive
#5

I appreciate that, Dimitry. Like Dimitry mentioned, everyone here is genuinely thrilled about what's coming up for BEMPEG and the chance for this significant IL-2-based therapy to help a great many people fighting cancer. Nektar, as you're aware, has assembled a really robust and well-diversified clinical pipeline, and we've positioned ourselves as the frontrunner in cytokine therapeutics. Our aim is to go after major opportunities in oncology — solid tumors, liquid tumors, and past cancer too, across a wide spectrum of autoimmune conditions. To seize these major opportunities, we're pushing clinical studies forward with 2 big programs, NKTR-255 and NKTR-358; on top of that, we have a strong research pipeline exploring immune-based agents for cancer and autoimmune diseases alike. Let me begin with NKTR-255, which engages the entire biology of the IL-15 pathway, delivering functional activation and homeostatic regulation of IL-15 responses in immune cells — specifically natural killer cells, CD8 T cells, and immune memory subsets. Being a full agonist of that IL-15 pathway, NKTR-255 is able to pair with many different mechanisms, from targeted agents to cell therapies such as CAR-Ts and immunological checkpoints as well, potentially boosting how well those agents work. Through our initial dose escalation efforts, we've seen natural killer cells and CD8 T cells rise consistently across several tumor types, among them multiple myeloma, Non-Hodgkin lymphoma, colorectal cancer, and head and neck cancer. NK cells have gone up by as much as ninefold, and our pharmacokinetic profile is extremely predictable, which lets us administer NKTR-255 every 3 or 4 weeks; crucially, we observe gains in NK and CD8 T cells even among the hardest-to-treat patients, such as multiple myeloma patients whose bone marrow is compromised. That's a really key characteristic of NKTR-255, and it ought to make NKTR-255 suitable both as a monotherapy and alongside targeted antibodies. We likewise see promise in boosting CAR-T persistence. At ASH, we presented data on a group of 4 patients in our NKTR-255 study with heavily relapsed and refractory NHL who had also received CAR-T among their earlier treatments. 3 of those patients were more than a year out from their CAR-T infusion, and every one of them had minimal detectable CAR-T at baseline before joining the NKTR-255 clinical study. It was very encouraging to find that among all 4 patients with detectable CAR-T at baseline, those cells rose substantially following NKTR-255 treatment. These early findings underscore the possible role for NKTR-255 as a CAR-T potentiator. Moving ahead in the clinic, we'll assess dosing NKTR-255 soon after CAR-T infusion. We're running a study alongside Dr. Cameron Turtle at the Fred Hutchinson Cancer Center to determine whether we can produce even more durable responses for patients. As was mentioned previously during this call, the FDA has just given us the green light for the trial to move forward; within this trial, we'll be assessing multiple dosing schedules of NKTR-255 administered near the point when CD19 CAR-T cell therapy is given. Naturally, our original approach has centered on pairing it with antibodies to work via an ADCC mechanism of action, and we have a strong clinical program underway covering both liquid and solid tumors. Regarding our Phase I/II trial of NKTR-255 combined with cetuximab in individuals whose head and neck cancer and colorectal cancer has relapsed or is refractory, we remain within the dose escalation stage, with sequential patient cohorts receiving increasing doses of NKTR-255 every 21 days alongside weekly cetuximab until we identify either the maximum tolerated dose or the recommended dose for advancing into the expansion cohorts; in our trial for relapsed refractory hematological malignancies, the agent has shown very good tolerability when used as monotherapy. We anticipate finishing the dose escalation portion of the trial during the first part of 2022, after which we'll transition into the expansion phase combining it with rituximab or DARZALEX FASPRO. The initial arm of the trial will assess NKTR-255 as monotherapy or paired with rituximab in third line or later follicular lymphoma or low-grade non-Hodgkin's lymphoma. The subsequent arm will assess NKTR-255 as monotherapy and combined with DARZALEX FASPRO in third line or greater multiple myeloma. Lastly, the third arm will assess NKTR-255 as monotherapy for non-Hodgkin's lymphoma patients whose disease has previously progressed after approved CD19 CAR-T cell therapy; we recently broadened our program via a collaboration agreement with Merck KGaA to assess NKTR-255 combined with avelumab in the urothelial carcinoma maintenance setting following chemotherapy as part of the JAVELIN Bladder Medley study. This collaboration rests on a distinctive scientific rationale for pairing NKTR-255 with avelumab, which, as a reminder, is a PD-L1 inhibitor featuring an ADCC active IgG1 Fc region. The NKTR-255 combination arm of the study intends to enroll 72 patients and will be compared against an avelumab control arm. Results from this trial will assist in establishing whether a registrational pathway exists for NKTR-255 in this setting where avelumab already holds approval. In the avelumab alliance, Merck and Pfizer are sponsoring the trial with Merck conducting the study, and they remain on track to launch the study next quarter. Let's now shift to our immunology program, NKTR-358. As Howard mentioned previously, we're highly encouraged by the extensive development scope and overall progress of the NKTR-358 program being carried out by our partner, Eli Lilly. Numerous autoimmune and inflammatory conditions, such as systemic lupus and ulcerative colitis, are linked to diminished Treg numbers, impaired Treg function and/or lowered IL-2 production. Through NKTR-358, we've employed a wholly distinct strategy using our pegylation chemistry to harness the immune regulating capacity of IL-2 by selectively stimulating Tregs. So, with NKTR-358, what we're aiming to do is tackle the Treg abnormalities that sit underneath autoimmune disease, and to create an IL-2-like molecule capable of stimulating Tregs selectively and more effectively than low-dose IL-2 does. What we've seen coming out of this program has genuinely strengthened how confident we are in that approach. In our multiple ascending dose trial involving lupus patients, NKTR-358 produced a reduction in lupus skin disease activity that was dose-dependent, measured through the Class 8 activity score among the subset of 18 patients whose baseline score was at least 4; and that data, together with the PK, PD and safety information gathered in this Phase Ib lupus trial, is what prompted Lilly to launch a Phase IIb dose range finding study in 280 lupus patients, which is progressing well and enrolling nicely. Then, late last year, Lilly shared exciting proof-of-concept results in a second dermal disease pathology, moderate to severe atopic dermatitis. That 12-week study tested 2 doses of NKTR-358 against placebo, and afterward patients were followed for a considerable stretch beyond their final dose of the therapy. With NKTR-358 treatment, eczema area and severity index scores fell in a dose-dependent way, with roughly a 70% maximum reduction in scores of week 12 at the highest dose tested. And the efficacy observed there aligns well with the current standard of care, DUPIXENT, which calls for 16 weeks of treatment with that agent; but the most fascinating thing we saw in the study, clearly, was that when patients were examined 36 weeks after dosing with NKTR-358 therapy had stopped, their skin scores were still very low and actually fell even more across that extended period. That has both us and Lilly quite excited about the durability potential for NKTR-358; and these results really underscore our hypothesis that boosting regulatory T-cell function might indeed address the immune pathology underlying the disease and yield a durable clinical signal, just as we see here in atopic dermatitis, long after treatment ends. NKTR-358 represents a first-in-class mechanism. And as we recognized when this development program began, NKTR-358 may be able to treat the underlying disease pathology and deliver disease-modifying effects. What that means is that, should we succeed, NKTR-358 could genuinely transform how autoimmune disease is treated. The Phase II program for NKTR-358 consists of the ongoing 280-patient Phase II study in lupus, a second ongoing Phase II study in 200 patients with ulcerative colitis, a third Phase II study planned in atopic dermatitis, and a fourth Phase II study in an autoimmune indication that has yet to be announced, expected to begin later this year; with these trials making great progress, we anticipate a steady stream of data from these Lilly studies over the next 12 to 18 months. And with that, I'll hand the call over to Gil.

Gil Labrucherie

executive
#6

Jonathan, thanks, and hello everyone — good afternoon. We put out our complete 2021 fiscal-year results today via the earnings press release. On this call, I'll share the annual financial guidance we're providing for 2022. Starting with cash: we ended 2021 in a very solid financial position, with about $800 million across cash and investments, and zero debt. In addition, our BMS partnership carries highly meaningful near-term milestones on both the regulatory and commercial launch fronts, contingent on positive results from the BEMPEG registrational trials. Let me give you more specifics about how those milestones are structured. When it comes to the initial indication, $60 million in milestone payments are linked to health authority filings for BEMPEG across the U.S. and EU. Another $500 million in commercial launch milestones are divided evenly, with half for the first commercial sale in the U.S. and half for the first commercial sale in the EU. Then there's $65 million in milestones connected to regulatory submissions and commercial launch in Japan. For each of the following 3 indications, $30 million of milestones relate to health authority filings in the U.S. and EU, $200 million in commercial launch milestones are split equally between the first commercial sale in the U.S. and the first commercial sale in the EU, and $30 million in milestones are tied to regulatory approval submissions and commercial launch in Japan. Ahead of walking through the detailed components of our 2022 financial guidance, I'd like to review several important assumptions that shaped it. If any of our registrational trials for BEMPEG read out positively during the first half of 2022, then depending on how filing and review schedules play out, there's a chance BEMPEG wins approval and reaches the market as soon as late 2022. Having said that, when it comes to the financial guidance we're providing for this year, the only regulatory filing milestones factored into our estimates for revenue and cash position are those for 2022. Any revenue or cash receipts tied to possible commercial launch milestones would land in 2023. Naturally, we'll revise that guidance when it makes sense, drawing on whatever additional information reaches us over the course of the year. Moving on now to what we're projecting financially for 2022. On the cash side, we anticipate closing out the year with roughly $400 million across cash and investments, and net cash usage for 2022 should look fairly similar to what we saw in 2021. Wrapped into our anticipated 2022 cash position is $100 million from BMS collaboration milestones linked to regulatory filings for BEMPEG. For 2022, we anticipate GAAP revenue in the range of $185 million to $195 million. That figure includes $100 million in BMS collaboration milestones tied to BEMPEG regulatory filings. Of those milestones, we presently expect roughly $70 million to be recognized during Q3, while the remaining $30 million would be recognized in Q4. If you set aside the milestones, the other $85 million to $95 million of GAAP revenue should be recognized fairly ratably across the four quarters of 2022. Breaking down the portion of revenue not linked to milestones, it consists of $70 million to $75 million in noncash royalties along with $15 million to $20 million from product sales. Looking ahead to 2022, our GAAP R&D expense should come in at about $500 million to $525 million. Within that total, you'll find approximately $65 million to $70 million from depreciation and stock compensation, both noncash items, plus another $30 million to $35 million of noncash development expense related to the head and neck program that SFJ Pharmaceuticals is backing. The money we're putting into R&D throughout 2022 will move forward our extensive pipeline of immune-modulating medicines and prepare BEMPEG for commercial launch. Alongside our partners, we're supporting 6 registrational studies for BEMPEG. During this year, we anticipate wrapping up enrollment of roughly 950 patients in the PIVOT-12 adjuvant melanoma study at around the midpoint of the year, and we also expect enrollment in the head and neck study to ramp considerably. Manufacturing of BEMPEG for commercial launch is ongoing, and those costs will keep showing up in R&D until BEMPEG wins approval — at which point we would capitalize our commercial manufacturing into inventory and run it through cost of goods sold. When it comes to NKTR-358, we will cover our 25% portion of development costs for 4 Phase II Lilly clinical studies spanning lupus, ulcerative colitis, atopic dermatitis and one further immune indication. Regarding NKTR-255, our dose escalation work in blood cancers and solid tumors is nearing completion. This year, we'll start enrolling patients in several expansion cohorts where the drug is paired with ADCC antibodies. Beyond that, we'll keep pushing our research forward so additional programs can join our clinical pipeline in future years. For 2022, G&A costs should land somewhere in the range of $175 million to $195 million, and that figure includes roughly $35 million to $40 million in noncash depreciation along with stock compensation expense. As I said before, we are right now building out our commercial capabilities in a deliberately staged way, centered on distribution and market access, so that we're ready for BEMPEG commercial launch as early as the close of 2022. During the first half of 2022, we will keep gating our commercial investments carefully, ahead of getting positive top line data from our registrational studies that would support regulatory approval filings. Consequently, we don't anticipate G&A being ratable across 2022, since commercial activities are set to rise in the second half once positive top line data from the BEMPEG registrational studies arrives. Our noncash interest expense tied to our royalty monetizations should come in between $25 million and $30 million. One more thing worth flagging: within nonoperating expense, we record movements in the fair value of the derivative liability tied to our development programs, and the magnitude of that item may swing considerably over the course of this year, with the outcome hinging on the readout from the metastatic melanoma trial. Having covered all of that, we're ready to open the line for questions. Operator?

Peter Lawson

analyst
#7

I appreciate how much information you provided during this call. As we consider those 3 Phase III data releases, could you share how much we ought to infer across melanoma, RCC, and bladder for the BEMPEG studies?

Jennifer Ruddock

executive
#8

Certainly. Thanks, Peter. Dimitry is the right person for that question. Dimitry?

Dimitry Nuyten

executive
#9

Absolutely, and I appreciate you raising that. What we have here are what I tend to describe as separate attempts, each standing on its own. To begin with, the indications were, naturally, chosen with great care, grounded in what you might call IL-2 validation, and that applies in particular to melanoma as well as to renal cell carcinoma. When it comes to bladder cancer, that is an entirely distinct indication. We assembled, I would say, robust early-stage evidence spanning these various indications. That said, when you consider possible read-through, the tumor types involved differ considerably. The trial designs themselves are not alike. To be specific, with melanoma, what we are doing is layering on top of the existing standard of care by pairing with nivolumab and then measuring that against nivolumab by itself. In the renal cell setting, though, our approach pairs two I-O agents and sets that against a TKI strategy. So on the whole, I would characterize the read-through as minimal, and each of these really does represent an independent shot on goal.

Chris Zopf

analyst
#10

CJ Zopf here, sitting in for Chris tonight. Of course, everyone's on edge waiting for those Phase III readouts due later this half. Gil, we really appreciate you walking us through how the spend could shape up given the assumptions you laid out. If things unfortunately go the other way and the trials aren't positive, what should we keep in mind regarding possible shifts in the spend trajectory?

Jennifer Ruddock

executive
#11

Yes. Gil, would you like to handle that?

Gil Labrucherie

executive
#12

Right, and as you know — as we laid out, when it comes to what we've assumed in the guidance, positive data from the BEMPEG trials is what we expect. Naturally, you can picture that we've got certain backup options should success not come our way, unlikely as that is. Still, bringing up or even considering such options strikes me as far too soon; what we're doing is definitely preparing for success, and we're set to make whatever tweaks become necessary down the road.

Cheng Li

analyst
#13

This is Cheng calling in on Jay's behalf. Perhaps just a single question regarding 255. I'm simply curious about your perspective on the chance to work together on 255 alongside cell therapy. And on a separate note, I'm wondering about the trial with CAR-T that was recently started. At what point will 255 be dosed — within the CAR-T? And will dosing happen only once, or will it be given on a periodic basis?

Jennifer Ruddock

executive
#14

Yes. I appreciate that. JZ, would you like to elaborate a bit further on our strategy in cell therapy and the CAR-T study? Thank you.

Jonathan Zalevsky

executive
#15

Definitely, and I appreciate you raising that. When we first began working alongside Cameron Turtle at the Hutch, one thing we noticed was that we conducted quite a few preclinical investigations together. As you know, he truly ranks among the founding figures in this entire area. Our thinking was built on the finding that individuals showing the greatest IL-15 levels after conditioning tend to achieve some of the strongest results after receiving a CAR-T cell therapy transplant. That means the opening here involves supplying an outside source for the IL-15 pathway to assist in this context. What initially got us truly enthusiastic was seeing, in those early preclinical investigations, that giving NKTR-255 was able to rescue subclinical doses of CAR-T cells in a preclinical model. Those CAR-T levels are so small that they barely deliver any tumor control at all. Yet when combined with 255, not only do the tumors get destroyed, but the animals sustain long-term persistence of effect. You could repeatedly rechallenge them with the same tumors, and they stay entirely tumor-free for many, many months following treatment. The study that has since been broadened into this is likewise being conducted by Cameron Turtle at the Hutch, and it essentially builds forward from those initial preclinical investigations toward the ASH data I summarized in patients long past their earlier transplant, moving into a context where we will administer NKTR-255 far more contemporaneously alongside the CAR-T therapy. So just as you noted, in this case 255 gets given very close in time to when the CAR-T is administered. And as you mentioned, you have this capacity to keep treating; we will go on treating with NKTR-255 for a prolonged stretch after the original CAR-T transplant, with the chance in every one of these cases to boost persistence of the CAR-T cells and ultimately, hopefully, enhance the efficacy and durability observed with these therapies. Thanks for the question.

Jessica Fye

analyst
#16

At what point do you anticipate having mature overall survival data from the frontline melanoma trial? And what is the smallest PFS hazard ratio that study could detect?

Jennifer Ruddock

executive
#17

Jess, thank you. Dimitry, I'll ask you to handle those 2.

Dimitry Nuyten

executive
#18

Yeah, absolutely. I appreciate you asking that. Let me begin with the hazard ratio for PFS. Like we mentioned earlier, we haven't provided any extra or in-depth direction regarding our statistical analysis plan. I'd say it's pretty unusual for a company to reveal such specifics before a complete publication comes out. We've discussed clinical relevance in the past, and I've stressed 2 points. To begin with, as a sort of benchmark or reference trial, you can look at the CheckMate 067 study for plenty of particulars; and our trial is properly built to identify a clinically meaningful hazard ratio, so to speak. On the subject of the survival analysis, that's another area we haven't addressed. We aren't offering any direction about event counts or timing. All I can say is that it's 1 of the 3 co-primary end points; for a regulatory path, survival data isn't necessary. PFS on its own is a registrational end point, and survival data, as I believe is understood for numerous other melanoma trials, trails considerably behind, which naturally is a positive for patients. They're surviving much longer than they do without disease progression. So that's something we'll provide, shall we say, updates about down the road, but not right now.

Greg Harrison

analyst
#19

Suppose the melanoma results come back positive, yet they're possibly only on par with or not obviously better than ipi/nivo and CheckMate 067 — what would that mean for how you move ahead with commercialization? Put another way, do you see other ways BEMPEG could stand apart and let you capture a portion of that market?

Jennifer Ruddock

executive
#20

Thanks, Greg. I'll hand that one over to Dimitry too. Thank you, Dimitry.

Dimitry Nuyten

executive
#21

Absolutely, and I appreciate that question. This is not a straightforward matter, in my view. On previous calls, I've mentioned more than once that median PFS is, naturally, just one of several measures worth examining. The hazard ratio, I'd argue, is another. Were we to take your premise that hazard ratios come out comparable, then there would be — how should I put it — numerous other distinguishing factors within our trial that we could report and highlight for the sake of patient value. As an example, one such factor, which we demonstrated in the PIVOT-02 data, is the remarkably strong CR rate we observed. That clearly serves as an early indicator of possible long-term benefit; and the CR rate, naturally, delivers an advantage to a meaningful number of patients, though maybe not to 50% of them. As a result, it may fail to reflect median PFS, yet it could reflect a highly meaningful minority of patients enjoying very durable benefits. So that stands as one key differentiator we intend to examine; and drawing on the safety data we've already shared, that represents another factor we believe could be a particularly powerful differentiator, especially concerning ipi/nivo, given a Grade 3/4 AE rate above 50%.

Rob Hazlett

analyst
#22

I appreciate the extra information about what's coming up on the milestones. I'll squeeze in just two quick questions. First, can you go over once more what was the same or different regarding the patient population that got enrolled in the Phase II compared with the Phase III trials for first-line metastatic melanoma? Second, sadly, a war is going on — the sanctions, as we're aware, have been largely financial aimed at the Russian Federation, though not every one of them. You have certain sites located there. Do you expect any difficulties when it comes to obtaining data from any of your upcoming trials?

Jennifer Ruddock

executive
#23

I'll begin with the initial portion of that question, which is for Dimitry, concerning the patients who were enrolled in the Phase III as opposed to the Phase II; and for the latter portion of the study, I'll have Howard weigh in regarding the changing situation in Ukraine. Dimitry, would you like to address that?

Dimitry Nuyten

executive
#24

Absolutely. I appreciate you asking that. So, up until the point when our full data set gets published, we won't know or reveal the precise patient characteristics. That means, regarding the share of patients who have particular characteristics, we're not able to say anything at this time. It's a blinded trial, as you're aware. On the whole, the criteria for inclusion are quite comparable; and we've ensured that we have, shall we say, solid representation across the various risk factors. And, as we've discussed previously, we stratify across a number of key risk factors so that patients with those different risk factors end up spread evenly across the 2 arms. So we have confidence that the Phase III trial, a global Phase III trial, is going to capture, shall we say, the wide range of different prognostic and predictive factors among patients with metastatic melanoma.

Jennifer Ruddock

executive
#25

Thanks, Dimitry. Howard, would you like to say something about how things are developing in Ukraine?

Howard Robin

executive
#26

Absolutely, happy to address that. Well, it's clear that watching this unfold is heartbreaking, and we feel deeply for the people of Ukraine — seeing what is happening there is incredibly hard. I believe everyone would share that sentiment. What I can share is that Nektar has no vendors, no testing labs, no raw material supply chain, and no clinical sites located in the Ukraine, so none of those studies took place there. We're not expecting any — and yes, we've examined this matter quite thoroughly, it's a great question — but we're not expecting any danger of losing databases, any issues with plans to analyze top line data and/or any of the study results that are planned for BEMPEG stemming from the conflict between Ukraine and Russia; nor do we currently see any filing risks. Naturally, we'll keep watching the situation closely; we will — we'll figure out whether any issue arises. That said, right now, nothing seems to be putting these trials or the database locks in jeopardy. And once more, we have zero sites in the Ukraine whatsoever. I hope that clears it up for you.

Mara Goldstein

analyst
#27

I'd like to ask about 358 and the choice to opt in. What might the timing look like, and what factors would gate that? And would it be — does that time frame line up with this year, when you expect clinical data from studies that could potentially be registrational?

Jennifer Ruddock

executive
#28

Thanks, Mara. I'll have Gill handle that one. Gil?

Gil Labrucherie

executive
#29

Right, Mara. Regarding how we've set up the Lilly partnership: once they decide to move into Phase III, there's a defined window for us to opt in, sharing both development and funding obligations for that Phase III trial at as much as 25%. That participation secures the top royalty bracket — as Howard noted before, that's mid-teens to low 20s, climbing rapidly into the low 20s. We haven't reached that decision point yet, but honestly, when we consider the scale of these indications and review what NKTR-358 has already delivered — results that are remarkably promising — our expectation would be to cover our share in order to capture the maximum royalty rate. Naturally, though, the call will have to be made at that moment, or whenever Lilly starts pursuing various indications in Phase III guided by the Phase II data.

Tsan-Yu Hsieh

analyst
#30

Thank you. I've got something to ask Dimitry. Dimitry, you brought up the RCC trial during Q2 that might be subject to resizing depending on what the DSMB recommends. How exactly is that call going to be reached? Does it hinge on overall survival response rate? And do you look at the whole population, or only the intermediate high-risk group? My other question also ties into RCC. You brought up the 250 triplet study. Is that still running? I'd just like to know where that trial stands.

Dimitry Nuyten

executive
#31

Certainly. I appreciate the question. Let me take the second part first, since it's fairly straightforward. That trial continues to run. So it's moving along. No guidance has been provided by us regarding data readout, but it is ongoing. On the first part of what you asked, let me just stress for everybody, this isn't a resizing of the trial. It isn't a sample size re-estimation; rather, it's an event size re-estimation for OS events. And it rests on, shall we say, modeling our statistical group gave the DMC prior to the trial's start, in order to optimize, shall we say, the event rate for survival among intermediate and poor risk patients enrolled in the trial. I hope that addresses your question.

Howard Robin

executive
#32

Alright, thanks to all of you, and I appreciate you being with us today. If you look at how many therapeutic areas we're involved in, and just how broad our pipeline is, I feel a great deal of pride in this company for having created such a robust and wide-ranging clinical pipeline on the foundation of a new science; plus we've got 17 clinical trials underway in immuno-oncology and immunology. With every one of these programs, we're advancing BEMPEG, NKTR-255, and NKTR-358, each of which delivers distinct value within our pipeline on its own and targets sizable patient populations. Naturally, we also have further research programs that we're getting ready for the clinic in cancer and autoimmune disease. And keep in mind something crucial regarding BEMPEG IL-2. IL-2 has a mechanism that is well understood. Through our technology, we came up with a substantially improved IL-2. That's the reason we're eager for the BEMPEG melanoma data in the very near future. So for Nektar, we're definitely entering a busy and thrilling period. I'd like to express gratitude to our employees for their efforts and their hard work, and I want to thank our shareholders for sticking with us. And we're looking forward to giving you updates on how we're progressing in the very near future. So please stay tuned. Thank you very much.

Operator

operator
#33

We appreciate it; that brings an end to the call for today. Thanks for joining us, and at this point you're free to hang up. Hope everyone has a great day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Nektar Therapeutics transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Nektar Therapeutics earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nektar Therapeutics or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.